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Abstract
Current high-throughput DNA sequencing technologies have the ability to gen-
erate large amounts of high-resolution genomic data. The high dimensionality
in combination with the substantial levels of technical errors and biological vari-
ability typically present in the data make, however, the analysis challenging.
Tailored statistical methods are therefore crucial for reaching valid biological
conclusions. In this thesis, such methods were developed and applied to address
research questions in biology and medicine.
First, a method for identiﬁcation of tumour-speciﬁc (somatic) mutations
was developed, which included steps for noise-reduction, sensitive detection of
DNA alterations and removal of systematic errors. In Paper I, the method was
applied to exome-sequenced paired normal–tumour samples from pheochromo-
cytoma patients. A signiﬁcantly higher mutation rate was found in malignant
compared to benign tumours and three genes with recurrent somatic mutations,
exclusively located in malignant tumours, were identiﬁed. In paper II and III,
somatic mutations were identiﬁed in patients with acute myeloid leukemia and
evaluated as biomarkers in personalised deep sequencing analysis of remain-
ing cancer cells after treatment. In paper III, a statistical model correcting
for position-speciﬁc errors in the data was developed and shown to provide
superior sensitivity compared to standard techniques. In paper IV, clinically
relevant molecular subgroups of metastatic small intestinal neuroendocrine tu-
mours were identiﬁed based on miRNA gene expression proﬁles. Survival analy-
sis and subsequent validation suggested miR-375 as a prognostic biomarker. In
paper V, a hierarchical Bayesian model for detecting diﬀerences on nucleotide
level between microbial communities is proposed. By including between-sample
variability and utilizing a shrinkage approach, the model was able to perform
well both in cases of few samples and high biological variability. Finally, the
model was used to detect antibiotic resistance mutations in bacteria.
This thesis demonstrates that dedicated statistical analysis and knowledge
of the underlying error structure present in high-dimensional biological data is
of importance for enabling accurate interpretation and sound conclusions.
Keywords: high-throughput sequencing, somatic mutations, cancer genetics,
personalised diagnostics, metagenomics, hierarchical Bayesian modelling
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Chapter 1
Introduction
In all cells of all organisms, the genetic material contains information regard-
ing how the cells should develop and function. Parts of the genetic material
are partitioned into genes, i.e. units that hold information about how other
molecules, such as proteins, should be build. All the genetic material in a
cell is collectively called the genome. Diﬀerences in the genome determine,
together with the encountered environment, our diﬀerent traits, development
and responses. The evolution of new functions and organisms is possible due to
changes in the genome. The genetic material consists of DNA molecules, each
constructed of a long chain of four diﬀerent building blocks. These are collec-
tively called nucleotides and are denoted A, C, G and T. To permit analysis of
how the information encoded in the DNA molecules govern biological processes,
the information must be read. That is, the exact order of the nucleotides along
the DNA molecule needs to be determined. The term "sequencing" refers to
this process.
Until recently, sequencing was a time-consuming and costly task. For exam-
ple, when the ﬁrst human genome was sequenced, it was a large collaborative
project that required more than 10 years to complete (Lander et al., 2001).
An early strategy for investigating the association of a property with varia-
tions in the human genome was, therefore, to only read a very limited set of
positions instead of the whole sequence. However, new innovative techniques
for DNA sequencing, commonly referred to as the next-generation sequencing
(NGS), have dramatically lowered the cost and eﬀorts, and revolutionised the
ability to characterise genomes (Mardis, 2011). It is now possible to compare
information for the whole human genome, or substantial parts of it, from many
samples. The relation between genetic alterations and diﬀerent phenotypic
properties, such as, for example, diseases, can thereby be investigated at an
unprecedented resolution.
An impressive example of what is now possible is the whole-genome se-
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quencing of in total 15,220 Icelanders, where the data for the ﬁrst 2,636 in-
dividuals were reported in 2015 and then updated to the current set in 2017
(Gudbjartsson et al., 2015; Jónsson et al., 2017). The data is paired with other
unique resources for the Icelandic population, such as a genealogy for the nation
documented several hundred years prior, access to nationwide healthcare infor-
mation and additional DNA sequence data for more than 150,000 Icelanders
previously analysed at a lower resolution. In Gudbjartsson et al. (2015) the
landscape of genetic variants in the human genome in relation to, for exam-
ple, functional annotation and gene position is described. Furthermore, three
examples of connections between genetic variants and diseases found using the
data are presented, and additional such ﬁndings have been reported in subse-
quent articles, see for example Oddsson et al. (2015) and Haraldsdottir et al.
(2017). Even larger projects are ongoing, reﬂecting that availability of genome
sequencing data will continue to increase (Turnbull et al., 2018).
The alterations in the nucleotide sequences that give rise to the genetic
variability are called mutations. The diﬀerent genetic variants that mutations
create are called alleles. Mutations can occur in several diﬀerent ways. As a
ﬁrst example, there can be an exchange (also called substitution) of one nu-
cleotide for another, which will herein be denoted a single nucleotide variant
(SNV). Furthermore, one or a few nucleotides can be inserted or deleted from
the DNA chain, and such mutations are called insertions and deletions, respec-
tively, or simply indels. These small-scale mutations are a focus in the work
described in this thesis. A well-known example of such mutations are SNVs
and indels in the BRCA1 gene, changing the properties of the encoded protein
and leading to an increased risk for breast cancer (King et al., 2003). However,
there are also mutations on a larger scale, with the ampliﬁcation or loss of
larger regions up to whole chromosomes (a whole DNA molecule) or structural
rearrangements within or between chromosomes. An example is the gain of
an extra copy of chromosome number 21 or parts of it, resulting in Downs
syndrome in the carrier. Although mutations can have damaging eﬀects, it is
important to remember that they are a prerequisite for evolution and the gain
of new beneﬁcial properties. One example is a mutation in the FUT2 gene that
gives rise to resistance against winter vomiting disease (Thorven et al., 2005).
1.1 Cancer genetics
In cancer, a number of mutations alter the normal functions of a cell and turn
it into a cancer cell with enhanced ability to, for example, grow, divide, invade
other tissue and resist cell death (Hanahan and Weinberg, 2011). The diﬀerent
cancer types constitute a heterogeneous group of diseases that can have large
diﬀerences in their genetic causes. Even within a speciﬁc type of cancer, such as
breast or lung cancer, there are many diﬀerent combinations of mutations that
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can give rise to a tumour (Vogelstein et al., 2013). The mutations harboured
by a speciﬁc tumour inﬂuence, for example, the aggressiveness of the disease
and the ability of the tumour to metastasise, i.e. to spread to other parts of
the body (Armaghany et al., 2012; Brodeur et al., 1984). Furthermore, the
response to treatment can be dependent on which mutations that are present
in the tumour, and subsequent mutations can give rise to drug resistance during
treatment (Garnett et al., 2012; Zahreddine and Borden, 2013; Nilsson et al.,
2009). It is therefore important to characterise which mutations that cause
diﬀerent types of cancer and how they inﬂuence the progression and properties
of the disease. This is required both to gain a more thorough understanding of
tumour biology and to be able to develop better diagnostics and treatment.
However, the analysis regarding functional impact of mutations are impeded
by the fact that tumour cells have a high mutation rate. Many of the mutations
acquired during tumour growth are so called passenger mutations and do not
inﬂuence the progression of the disease (Martincorena and Campbell, 2015).
Additionally, a mix of inherited mutations, that exist in all cells of an indi-
vidual, and acquired mutations often together cause the tumour development
(Knudson, 1971).
To be able to utilise the knowledge about cancer mutations, and employ it
in a personalised cancer therapy, it is important to develop the use of mutations
as biomarkers and improve the techniques for identifying mutations in clinical
care. Here, it is often necessary to have a capability of detecting very low
amounts of cancer cells, and speciﬁc mutations in low proportions, to choose
an appropriate treatment as early as possible (Shin et al., 2017; Fiala and
Diamandis, 2018) .
In a cancer cell, the alterations in the genome lead, together with stimuli
from the surrounding, to a number of molecular changes, e.g in the level of RNA
molecules and in proteins. To study these changes, that mediates the altered
information in the genome, is important to fully understand the processes in
cancer cells. The information in the DNA molecules is transcribed gene-wise
to RNA molecules of which some are translated to proteins. Proteins are the
molecules that promote and provide control of the chemical reactions in the cell.
The number of messenger RNA (mRNA) molecules transcribed from a speciﬁc
gene relates to the amount of the corresponding protein. To examine changes in
the levels of diﬀerent mRNA molecules is a way of study the eﬀects of mutations
and the state of the cell, and the levels can also be used as biomarkers. For
example, an mRNA proﬁle that strongly predicts a short time interval until
developing metastases have been identiﬁed in tumours of breast cancer patients
(van’t Veer et al., 2002).
Large scale quantiﬁcation of mRNA levels can be accomplished by microar-
ray analysis. It is a technique that has been extensively used for more than 20
years, where the levels of mRNA for, in principle, all genes can be determined
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simultaneous by hybridising mRNA molecules to immobilised probes (Katagiri
and Glazebrook, 2009). With the advent of NGS, techniques for sequencing
RNA molecules and quantifying their levels have also been developed. RNA
sequencing allows for a wider dynamic range and detection of novel mRNA
molecules, such as fusion genes (Kukurba and Montgomery, 2015). The latter
refers to novel combinations of two genes, which can arise due to structural
rearrangements in the genome, and such mutations can be strong drivers of
cancer (Gao et al., 2018).
1.2 Genetic variability in metagenomes
Genetic variability is also studied in microbiology. Microorganisms are vital
parts of all ecosystems and organised in communities. These have historically
been diﬃcult to study due to their complexity. In particular, the methods have
been dependent on the ability to culture the studied organisms in a laboratory.
A microbial community can consist of thousands of species, and only a limited
number of those are straight-forward to cultivate using standard protocols.
However, with the advent of NGS techniques, the ﬁeld of metagenomics has
gained popularity. In metagenomics, all the genetic material from a sample
taken directly from the environment is sequenced, without any prior cultivation.
Thereby the genetic variability, and hence the compositions of species and
biological functions, and its connection to diﬀerent conditions and properties
can be investigated.
A better understanding of the processes in microbial communities is of great
importance in many diﬀerent ﬁelds, such as agriculture, waste water treatment
and medicine. For example, bacteria exist practically everywhere, both in the
environment and within humans. They often contribute to important functions,
such as the digestion process in the gut. However, bacteria can also cause in-
fections, and we are dependent on having antibiotics to treat those infections.
An emerging problem is bacteria that have become resistant to one or several
types of antibiotics. This phenomenon cause infections that are today easily
treatable to become life-threatening ones and can, in the long run, hamper
many modern medical procedures. For example, eﬀective antibiotics are im-
portant when performing surgery to prevent infections in wounds. Resistance
towards antibiotics typically depends on changes in the genetic material of the
bacteria. Mutations in protein coding genes is one way of acquiring resistance.
For example, only three SNVs in the genome of the bacterium Escherichia coli
is enough to make it highly resistant to certain types of antibiotics (Bagel et al.,
1999). To be able to advance our understanding of the mechanisms underlying
antibiotic resistance, one important component is thus to examine which mu-
tations that exist in bacteria and that are promoted under selection pressure
from antibiotics.
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1.3 Sequencing data and the statistical challenges
As described in previous sections, the new sequencing techniques have made it
possible to generate massive amounts of data and opened up a wealth of new
opportunities for analysis of genomes. There are, however, also a number of new
challenges related to data analysis and handling. The data is high-dimensional,
both in the sense that it contains information at nucleotide resolution for the
genetic material, and as a result of the new way the data is generated. In
addition, the error proﬁle of the data is fundamentally diﬀerent from earlier
techniques and requires careful bioinformatical handling and statistical evalu-
ation for adequate interpretation. (Mardis, 2011).
In general, NGS data can be generated in large amounts, but consists typ-
ically of small pieces with overlapping and noisy information that needs to be
concatenated and evaluated to reach consensus. After extraction of the genetic
material from the studied sample, the DNA molecules are heavily fragmented
and many such fragments are then sequenced rapidly and in parallel (Metzker,
2010). The term "massively parallel sequencing" is hence often used to describe
these techniques. By sequencing of millions, or even billions, of DNA fragments
from multiple cells each region of interest in the genome can be covered several
times. The reads (i.e., sequenced fragments) are then mapped to a reference
genome, generating piles of reads (Figure 1.1).
Figure 1.1: Sequenced DNA fragments are mapped to the human reference genome
and viewed by the visualisation tool Integrative Genomics Viewer (Thorvaldsdóttir
et al., 2013). The coloured vertical lines represent positions where there are discrep-
ancies (variant alleles) compared with the reference. On top, a histogram shows the
number of times each position is read.
When identifying mutations using NGS data, the task is to decide for which
5
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positions there actually are mutations and for which positions discrepancies
from the reference genome only represent errors in the data. The methods
need to be sensitive to detect mutations also in regions with few sequenced
fragments and mutations that potentially only exist in parts of the analysed
cells. At the same time, they need to have a low false positive rate, due to the
high dimensionality of the data with many positions to consider. Sequencing
the set of protein-coding genes in humans provides approximately 50 million
positions, and the whole human genome has more than 3 billion positions.
To achieve both high sensitivity and speciﬁcity is a non-trivial task, since the
data contains considerable levels of noise. These are due to errors introduced
during sample preparations and sequencing of the DNA, and to limitations of
the bioinformatical data processing (Olson et al., 2015). As an example, the
DNA fragments are ampliﬁed, i.e. copied, in the sample preparation, which
can lead to the insertion of incorrect nucleotides and bias in what parts of
the genome that are represented in the sample (Aird et al., 2011). Errors
introduced during sequencing are both random and systematic. For example,
errors occur more often at the ends of reads and in speciﬁc patterns in the
nucleotide sequence (Minoche et al., 2011). If not accounted for, these errors
can lead to biased results. Furthermore, it can be diﬃcult to determine where a
speciﬁc read should be placed along the reference genome, due to that the reads
are typically short (100 nucleotides is common) and contain multiple sequencing
errors. The problem is more severe for reads originating from regions with
repetitive patterns and from genes that are evolutionarily closely related and
hence may have similar nucleotide sequences (Treangen and Salzberg, 2011).
An accumulation of incorrectly placed reads can lead to discrepancies from the
reference genome that are artiﬁcial but look like true mutations.
Thus, to be able to employ NGS data and transform it into accurate in-
formation that can be used for new biological insights, knowledge about the
data structure and performing a sound analysis utilising bioinformatical and
statistical methods that properly handle the variability in the data, is crucial.
New and tailored computational and statistical methods are therefore vital to
take full advantage of the information present in the data and to reach correct
biological and medical interpretations.
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Aims
In the papers included in this thesis, biological data produced by high-through-
put techniques is utilised to assess genomic changes in cancer and bacterial
communities. In all cases, the data contains a high level of variability, stemming
from both biological and technical factors. The overall aim of this thesis is to
apply and develop bioinformatical and statistical methods that take the high
dimensionality and the variability of the data into account. In particular, the
objectives are to reduce the noise, model the variability and remove systematic
biases. This is vital to perform sensitive analyses and keep the false positive
rate low, and thereby be able to reach valid biological conclusions. The speciﬁc
aims are as follows:
1. Develop a method for identiﬁcation of somatic mutations in high-through-
put DNA sequence data. The method should be sensitive, have a low false
positive rate and include all the steps in the analysis starting from the raw
sequencing data and arriving at a set of annotated and carefully assessed
somatic mutations (Paper I-II).
2. Apply and adapt the developed method (Aim 1) to data from the can-
cers pheochromocytoma/paraganglioma and acute myeloid leukaemia, in
order to ﬁnd somatic mutations that are potentially relevant for tumour
development or as biomarkers (Paper I-III).
3. Develop a statistical model for quantifying low frequency mutations in
targeted deep sequencing data, in order to facilitate personalised diag-
nostics of leukaemia (Paper III).
4. Characterise the miRNA proﬁle of small intestinal neuroendocrine tu-
mours to search for molecular subgroups of clinical relevance and biomark-
ers for tumour development and outcome (Paper IV).
5. Develop a statistical model for the detection of diﬀerences at the nu-
cleotide level between groups of metagenomes, sampled from bacterial
communities encountering diﬀerent experimental conditions (Paper V).
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Chapter 3
Finding somatic mutations in
exome sequencing data
In Paper I and Paper II, the focus is on ﬁnding tumour-speciﬁc mutations in
protein-coding regions (the exome) for the cancer types pheochromocytoma/
paraganglioma and acute myeloid leukemia, respectively. To complement the
relatively brief methods sections in these papers, the bioinformatical and sta-
tistical approaches used to pre-process the raw sequencing data, identify can-
didate somatic mutations and ﬁlter for technical valid and biological important
somatic mutations are described in the sections below.
In a tumour cell, there is a mix of inherited (germline) mutations and mu-
tations that are speciﬁc to the tumour cells, denoted somatic mutations. The
search for somatic mutations is, in important aspects, diﬀerent from identify-
ing germline mutations. In particular, the ratio of sequenced fragments where
the mutation is expected to exist can diﬀer substantially. In human cells, all
but the sex chromosomes are inherited pairwise, resulting in two copies of each
gene. In general, all the cells in the body contain the same genetic material.
On average, a germline mutation is therefore expected to show up in 50% (het-
erozygous) or 100% (homozygous) of the sequenced fragments. That is, the
variant allele frequency (VAF) is expected to be 50% or 100%. However, in
samples from tumour cells this may no longer be the case. During development
and growth of a tumour, new somatic mutations are typically acquired. When
a new somatic mutation appears, the mutation event occurs in one of the tu-
mour cells. How successful that cell is in surviving and dividing into additional
cells with the same mutational pattern is dependent on its selective advantage.
tumours are therefore often heterogeneous and consist of multiple subclones,
meaning that the genetic material diﬀers among the cells. While some somatic
mutations can be common to all cells, due to an early mutation event or a large
9
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selective advantage, others exist only in subclones. Both types are important
to ﬁnd to fully understand the genetic cause of how a tumour originates, de-
velops and responds to treatment. Furthermore, samples from tumours often
contain normal cells to a certain extent. Tumour cells can also mutate to have
more or less than two copies of each gene. Altogether, this means that in a
tumour sample, the frequency of the variant allele for a somatic mutation can
take on values from, in principle, just above 0% to 100%. Thus, the assumption
concerning which VAF:s to expect in the data from a tumour sample must be
relaxed compared with those employed when searching for germline mutations
in a normal sample.
Another aspect is directly connected to the deﬁnition of a somatic mutation:
it should not be present in normal cells. A paired experimental design, including
samples from both normal and tumour cells from each patient, is therefore
needed. For each position, the tumour and normal sequence data is compared
and if variant alleles are present in the tumour sample but not in the normal
sample, a candidate position for a somatic mutation is, in principle, found
(Figure 3.1).
Tumor sample Normal sample
Figure 3.1: Sequenced DNA fragments aligned to the human reference genome and
viewed using the Integrative Genomics Viewer, where variant alleles are shown by
coloured letters. Variant alleles are detected in the tumour sample but not in the
normal sample, i.e., a candidate somatic mutation.
3.1 Pre-processing of the data
The purpose of pre-processing the data, before the actual identiﬁcation of the
mutations, is to correct or at least compensate for errors introduced during
sample preparation, sequencing and mapping to the reference genome.
We start from the point where we have access to the reads, i.e., sequenced
DNA fragments, and quality scores for each sequenced nucleotide (denoted
Q). The quality scores are related to the probability of a sequencing error, P ,
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according to
Q = −10 log10 P,
where the probability values are estimated during sequencing based on a range
of features for the detected signals. The ﬁrst step in the preprocessing is to
ﬁlter the data based on the quality scores to ensure that reads with overall low
quality are discarded. Additionally, during Illumina sequencing, the quality
often drops towards the end of the reads, and such stretches can be trimmed
oﬀ during the ﬁltering step (Minoche et al., 2011). In Paper I-III, we used
the tool PRINSEQ to perform quality ﬁltering and trimming (Schmieder and
Edwards, 2011).
Then, the reads are mapped (aligned) to the reference genome. That is, the
original position in the genome for each sequenced DNA fragment is searched.
A number of diﬀerent algorithms for aligning reads have been developed (Li and
Homer, 2010). In paper I-III, we used the Burrows-Wheeler Aligner (BWA) (Li
and Durbin, 2010) in paired-end mode, as recommended in the Best Practices
developed at the Broad Institute (Van der Auwera et al., 2013). Paired-end
refers to the type of sequencing performed, where the DNA fragment size is
aimed at being at least twice the length of a read and then the fragment is
sequenced from both edges. In this way, the mapping accuracy increases, since
information from both reads in a pair can be utilised. A mapping quality score
is assigned to each read, indicating how well the read matched the reference
sequence. Reads matching several intervals in the reference equally well are
ﬂagged by giving them a mapping quality score of zero.
The DNA ampliﬁcation used in the sample preparation can lead to the
same original fragment being sequenced twice or more, especially when a small
amount of DNA is used as the input material. To avoid accounting for the
same information several times, such duplicated reads must be removed. We
used a tool called Picard (http://broadinstitute.github.io/picard) to compare
read-pairs and mark those with the same genomic starting positions for both
reads as duplicates. In the duplicate marking, all reads from the same sam-
ple preparation must considered simultaneously. We noted that when using
formalin-ﬁxed paraﬃn-embedded (FFPE) tumour material in Paper I, the lev-
els of duplicates were generally much higher than for fresh-frozen (SF) material.
FFPE samples typically have more fragmented DNA than SF samples as well as
artiﬁcially introduced nucleotide changes (Do and Dobrovic, 2015). The higher
duplicate levels were likely due to the additional rounds of ampliﬁcation that
were needed in the sample preparation of the FFPE material. Additionally, the
Picard algorithm to a larger extent left duplicated reads unmarked in the data
from FFPE samples, due to inconsistent mapping of one of the reads in the
pair. This produced a signiﬁcant amount of false positive somatic mutations in
the FFPE material. We removed these by adding a down-stream ﬁlter requir-
ing each mutation to be found in several diﬀerent positions in its supporting
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reads. This problem was also noticed and solved similarly in another study
utilising FFPE material (Yost et al., 2012).
In regions with insertion or deletions in the sequenced sample, the mapping
algorithms often encounter diﬃculty determining whether to include indels or
mismatched nucleotides in the alignment, especially at the ends of reads. Each
read-pair is mapped independently of the others, which can produce inconsis-
tent decisions for diﬀerent reads at the same position. The process of correcting
for such inconsistencies is called indel realignment. Intervals that need to be
corrected are searched for, and all reads in such an interval are realigned to-
gether (DePristo et al., 2011). For a paired design with samples from normal
and tumour cells, it is important to perform indel realignment with all reads
from one patient included at the same time. Otherwise, diﬀerent consensus de-
cisions may be reached for the tumour and the normal samples, creating false
positives when inferring somatic mutations.
The quality scores for the nucleotides are used extensively in the algorithms
for identifying mutations and in the subsequent ﬁlters. However, the quality
scores contain systematic errors associated with, for example, the sequenc-
ing machine cycle and the sequence context. A process called base recalibra-
tion has been shown to eﬀectively reduce the bias in quality scores (DePristo
et al., 2011). In Paper I-III, we applied base recalibration considering the se-
quence context, sequencing cycle, original base quality score and read group
ID (Van der Auwera et al., 2013). The read group ID gathers reads from the
same sample preparation and machine lane.
3.2 Identiﬁcation of candidate somatic mutations
When trying to identify mutations, a decision has to be made whether dis-
crepancies from the reference sequence in the reads covering a speciﬁc position
reﬂect a true mutation or are a result of noise in the data. The statistical
method used to identify somatic mutations must be sensitive to detect low-
frequency mutations and mutations in regions with low sequence coverage. Si-
multaneously, high speciﬁcity is important due to the high dimension of the
data when a large number of genomic positions are considered. Additionally,
a mutation found in the tumour must be classiﬁed as somatic or germline, for
which the normal sample is utilised. Typically, a statistical model is used to
identify candidate somatic mutations, followed by ﬁltering the candidate list
to further remove false positives. The ﬁrst step is described in this section,
while the ﬁltering part is the topic of section 3.3. First, a short overview of
diﬀerent methods for the identiﬁcation of somatic mutations is given, followed
by a description of the methods used in Paper I-III.
One method that has been used to identify candidate somatic mutations,
especially in early studies, is a simple comparison between mutation lists from
12
3.2. Identiﬁcation of candidate somatic mutations
tumour and normal samples (Pleasance et al., 2010). One starts with using a
method for identifying germline mutations, such as, for example, the Uniﬁed
Genotyper (DePristo et al., 2011), on the normal and tumour samples sepa-
rately. Then, the list of mutations in the normal sample is subtracted from the
list of mutations in the tumour sample. One major disadvantage of this method
is that low-frequency mutations in the tumour are at risk of being missed, since
the statistical model incorrectly make the assumption of heterozygous or ho-
mozygous (VAF 50% or 100%) mutations. Furthermore, all germline mutations
that are missed in the normal sample but detected in the tumour will present
as false positive somatic mutations.
To improve performance, a number of dedicated statistical methods for
identifying somatic mutations have been developed. An overview of the avail-
able methods together with their underlying models is provided in Xu (2018).
The methods can be divided into diﬀerent categories, based on the assumptions
and models they employ. First, there are methods that still assume diploidy in
both tumour and normal samples, but instead of considering each sample sep-
arately, they perform a joint genotype analysis. SomaticSniper is an example
of such a method, where a somatic score is calculated based on the probability
of the tumour and normal sample having the same genotype (Larson et al.,
2012). The posterior probability for each combination of genotype in tumour
and normal samples, given the data, is calculated according to Bayes’ rule.
The prior probability of a speciﬁc combination is assumed to depend on the
expected rate of heterozygous mutations in the population and the typical rate
of somatic mutations. The genotype likelihood is calculated by assuming that
each observation of a read is an independent Bernoulli trial with a success
probability that is dependent on the genotype and the probability of an error
(taken from the base quality score).
A second category of methods instead models allele frequencies and allows
them to vary in a continuous range for the tumour sample. MuTect and Strelka
are two examples of such models, which we used in Paper I-III and are described
more in depth below (Cibulskis et al., 2013; Saunders et al., 2012). In a com-
parison of methods from these ﬁrst categories, the ones that allow for a range of
allele frequencies instead of assuming heterozygous/homozygous mutations are
shown to have much higher sensitivities for detecting low-frequency mutations
(Xu et al., 2014).
Furthermore, the method Varscan2, which was also used in Paper I-III and
described below, is a representative from the category of methods with heuristic
approaches that rely on thresholds on, for example, how many reads should sup-
port the variant allele (Koboldt et al., 2012). Methods using machine learning
constitute a fourth category, and an example is SNooPer, which trains a random
forest classiﬁer to divide candidate mutations between true somatic variants
and false positives (Spinella et al., 2016). A drawback is that a training set with
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known true variants and errors, where the samples are prepared and sequenced
in a similar way, needs to be available. Finally, methods based on haplotypes in-
stead of individual positions in the genome have been developed (Sengupta et al.
(2016), MuTect2: https://software.broadinstitute.org/gatk/documentation). In
MuTect2, candidate haplotypes in regions with variation are deﬁned via a lo-
cal de-novo assembly and the reads are then aligned to the haplotypes. This
process provides better accuracy in regions with several variants close to each
other and facilitates calling of indels.
Several articles comparing methods for the identiﬁcation of somatic muta-
tions have been published, for example Xu et al. (2014) and Cai et al. (2016).
An important remark from Cai et al. (2016) is that tuning of the model param-
eters and customising subsequent ﬁlters included in the methods often have a
large eﬀect on the quality and reliability of the output. It is thus recommended
to acquire knowledge about the applied methods in order to adapt parameters
and ﬁlters to the current application and data set.
To identify candidate SNVs in Paper I-III, we used the method MuTect
(Cibulskis et al., 2013). As said above, it allows for a continuous range of
possible frequencies for the sought somatic mutations in its statistical model.
To detect genomic positions with a mutation in the tumour sample, MuTect
applies a Bayesian classiﬁer. Two alternative models are considered for each
position harbouring variant alleles in the data, one denoted Mmf assuming that
a variant allele m with frequency f is present in the sample, and one denoted
M0 assuming that no variant alleles truly exist in the sample. The likelihood
of each model is calculated based on the sequence data, taking the read nu-
cleotides and their quality scores into account. For details on the calculation
of the likelihoods, see Online Methods in Cibulskis et al. (2013). The ratio
of the likelihoods times the prior probability for each model is calculated and
compared to a decision threshold log10 δT :
log10
L(Mmf )P (m, f)
L(M0)(1− P (m, f)) ≥ log10 δT .
The choice of δT determines how much more conﬁdence that is required in the
model with versus without a mutation, to declare that the position harbours
a candidate mutation. By assuming a constant prior probability P (m, f), the
equation can be rearranged to
log10
L(Mmf )
L(M0)
≥ θT ,
where θT is a constant, depending on δT and P (m, f), which can be tuned to
achieve diﬀerent sensitivities. When the performance of MuTect was evaluated
by Cibulskis et al. (2013), a δT of 2 and a prior probability for a somatic muta-
tion of 3× 10−6 were chosen, yielding a threshold of θT = 6.3. In Paper I-III,
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we instead chose to set θT = 8, representing both a lower prior probability
for somatic mutations in the studied tumour types and a higher ratio of the
likelihood needed to call a mutation. For each position with a candidate mu-
tation in the tumour, a similar method is used for the normal data to classify
the mutation as somatic or germline. The mutation frequency in the model
with a germline mutation is assumed to be 0.5 (assuming heterozygosity). To
assure that there is convincing evidence for not having a germline mutation at
the position, a ten times higher likelihood for the model without a mutation is
required to classify a candidate mutation as somatic. In addition, a ﬁlter for
the maximum number, or proportion, of variant alleles that are allowed to be
observed in the normal sample is added. In Paper I-III, we choose to reject
a candidate somatic mutation if three or more variant alleles, or a proportion
above 8%, were observed in the normal sample.
To identify candidate indels in Paper I-III, we used a combination of two
methods, Varscan2 and Strelka (Koboldt et al., 2012; Saunders et al., 2012).
In Varscan2, all positions in the normal and tumour samples are ﬁrst inspected
separately to assess whether a larger proportion of variant alleles is presnt in
the data than a user-deﬁned threshold. In Paper I-III, we set the threshold
to 0.05. For positions where the threshold is exceeded in the tumour but not
in the normal sample, Fisher’s exact test is used to test for evidence of a sig-
niﬁcant diﬀerence in allele frequency between tumour and normal samples. In
Strelka, a Bayesian approach is instead used. Brieﬂy, the VAF in the normal
sample is modelled as a mixture of heterozygous/homozygous genotypes and
noise. The VAF in the tumour sample is modelled as a mixture of the nor-
mal sample and additional somatic variation. Thereby, a continuous range of
possible frequencies for the sought somatic mutations are permitted, and base
qualities are taken into account. For full details regarding the statistical model
used in Strelka, see Saunders et al. (2012).
Finally, it is worth noting that before applying the statistical models de-
scribed in this section, all methods have their own prior ﬁltering regarding
which positions that have enough coverage data to be evaluated and which
reads that are of suﬃcient quality to be used. For each method utilised in Pa-
per I-III, we used the default settings (Cibulskis et al. (2013), Saunders et al.
(2012), http://varscan.sourceforge.net/).
3.3 Filtering of candidate somatic mutations
The methods used to identify candidate somatic mutations operates on data
from one position at a time, assuming that the sequencing errors are random
and independent, and further that all reads are aligned correctly. These as-
sumptions are in general not met. For example, reads can be aligned at the
wrong place or with wrong decisions concerning where to incorporate mis-
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matches/indels, and sequence errors tend to accumulate for certain preceding
sequence patterns. Thus, the whole error structure of the data is complex and
not fully captured by the models, and the list of candidate somatic mutations
often contains a high rate of false positives. The statistical models described
above are therefore in general complemented with diﬀerent approaches to ﬁl-
ter the list of candidate somatic mutations. For example, MuTect has multiple
numbers of implemented ﬁlters that we applied to the lists of candidate somatic
mutations in Paper I-III (Cibulskis et al., 2013). Important steps of the ﬁlter-
ing include removing mutations at positions with proximal gaps, i.e., where the
aligned reads spanning the position harbour surrounding indels, and mutations
where the variant alleles mainly sit at the start or end of reads. Furthermore,
positions where the mapping quality scores are low for the reads supporting
the mutation or indicate that many of the reads could have been placed equally
well at another region, are also excluded. Another example is the removal of
mutations with strand bias, i.e., where mismatches are seen mainly in one read
direction and thus can be assumed to be dependent on the sequence context.
However, the ﬁlters added to each method do not cover all systematic errors
that can occur. The paired design used when calling somatic mutations means
that data from each tumour sample is compared to data from the normal sample
in the same patient. The aim is primarily to exclude germline mutations,
but technical artefacts present in both both tumour and normal data are also
captured. To remove false positives due to rare but systematic position-speciﬁc
errors, not only the paired normal sample but all the normal samples can
be utilised. In Paper I-III, we used an approach where we screened all the
normal samples at all positions where candidate somatic SNVs were identiﬁed.
If two or more samples failed to meet the normal criteria (at most 2 reads
or 8% of the reads harbouring the variant allele) at a speciﬁc position, the
corresponding candidate somatic mutation was excluded. During analysis of
the data in Paper I-III, we also noticed that variant alleles were sometimes
identiﬁed recurrently at certain positions only for samples sequenced under the
same conditions. That is, the position-speciﬁc sequencing errors correlated to
the type of sequencing machine (e.g., HiScanSQ or NextSeq) and its settings,
including the chemistry version. An important aspect of the study design is
therefore to run paired samples together or, at least, use the same experimental
set-up. Furthermore, to fully utilise the screening of normal samples, it is
important to have access to as many samples as possible that are sequenced
under similar conditions.
We have now arrived at a list of somatic mutations that are evaluated and
ﬁltered from a technical perspective. One remaining question concerns which
of the somatic mutations that inﬂuence the disease in a crucial way and which
that are merely passenger mutations. It is noteworthy that this is an important
part of the aims in Paper I, while in Paper II and III, the focus is instead on the
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identiﬁcation of patient-speciﬁc genetic markers that are present in as many
tumour cells as possible.
A ﬁrst step towards elucidating the importance of mutations is to anno-
tate them with respect to gene name, location in functional elements, if any
amino acid substitution occurs and the (germline) population frequency of the
mutation. In Paper I-III, we used the tool ANNOVAR to annotate the list
of somatic mutations (Wang et al., 2010). Mutations with a population fre-
quency greater than 1% were excluded from the lists. In Paper II and III, these
common mutations were removed due to a higher likelihood of being missed
germline mutations, which would make them and thus unsuitable as tumour
cell markers. In Paper I, an additional reason for removing mutations that
are common in the population was that it is unlikely that such mutations are
the cause of the rare cancer disease studied herein. For mutations located in
protein-coding regions, only mutations resulting in a change in the amino acid
chain of the encoded protein (nonsynonymous mutations) were retained in Pa-
per I. A change in the amino acid chain is a prerequisite for altering the function
of a protein, but diﬀerent changes aﬀects the protein structure and function to
diﬀerent extents. As a further guidance for the functional consequences of the
somatic mutations found in Paper I, we also annotated the mutations with the
scores from ﬁve diﬀerent functional prediction algorithms (Liu et al., 2013).
A strong criterion for the inﬂuence on the disease is whether a gene is
mutated recurrently, i.e., has somatic mutations in several patients. However,
when analysing a large collection of samples or tumours with a high mutation
rate, recurrent mutations in a gene can occur solely by chance, especially for
large proteins. There are statistical methods to test the hypothesis that a gene
exhibits more mutations than expected according to the background mutation
rate (Raphael et al., 2014). In Paper I, such tests on the gene level were
not applicable due to the low somatic mutation rate in combination with a
heterogeneous disease and rather few samples. Instead, we high-lighted all the
genes that harboured recurrent mutations, with the exception of genes that
were previously suggested to often represent false positives in cancer studies
due to a large size or high mutation frequency (Lawrence et al., 2013).
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Chapter 4
Sensitive detection of
mutations using targeted
deep sequencing
In this chapter, we focus on methods for quantifying low-frequency somatic mu-
tations using sequencing data. The ﬁrst section provides an introduction, with
examples of applications, associated challenges and some of the key methods
that have been proposed. The remaining two sections consider the methods
that were applied and developed in Paper III. The application is introduced
in section 4.2, and the methods used to reduce the level of noise in the data
is described. In section 4.3, a novel statistical model with a position-speciﬁc
error correction is presented and discussed.
4.1 Introduction to targeted deep sequencing
As described in Chapter 3, there is in general an interest in detecting somatic
mutations in exome sequencing data at any frequency, including both mutations
common to all cancer cells, present at frequencies near 50%, and mutations that
are only present in subclones and hence show a lower variant allele frequency
(VAF) than 50%. However, exome sequencing and the methods described in
Chapter 3 have a lower limit with respect to the possible mutation frequency
for detection with suﬃcient conﬁdence. For example, in Paper I, we excluded
all candidate somatic mutations with a VAF below 5% to avoid large amounts
of false positives. This is both due to the available sequencing depth of the
exome sequencing data, where the coverage typically is around 100, and the
relatively high levels of noise. In many applications, however, there is a need
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to detect mutations at lower frequencies. One example, that was already men-
tioned in Chapter 3, is the analysis of biopsies from solid tumours that are
heterogeneous and/or include a large number of normal cells. In these cases,
the fraction of cells with a speciﬁc somatic mutations can be low (Shin et al.,
2017). Additionally, if the interest of a study focuses on clonal evolution, the
low frequency mutations in small subclones are important (Gerstung et al.,
2012).
Another example is the emerging area of analysing cell-free DNA (cfDNA)
in blood samples (often referred to as the analysis of liquid biopsies). It is
known that the blood plasma contains cfDNA and that the cfDNA is released
from diﬀerent parts of the body, including DNA from the foetus during preg-
nancy and DNA from tumours in cancer cases (Lo et al., 1997). Analysis of the
cfDNA during pregnancy can be used in prenatal testing, with the advantage of
analysis of the foetal DNA without invasive procedures such as amniocentesis
(Breveglieri et al., 2019). Future possible clinical applications for analysis of
circulating tumour DNA (ctDNA) includes monitoring of the disease burden,
prognostic determination, selection of treatment and monitoring for relapse (Fi-
ala and Diamandis, 2018). For example, the amount of ctDNA correlates with
the tumour size, tumour stage and metastatic burden. Furthermore, knowl-
edge concerning speciﬁc mutations in ctDNA can guide the treatment selection
through knowledge about the potential drug resistance or drug targets, as well
as the prognostic indication. Taking a liquid biopsy instead of images or inva-
sive samples avoids the risks associated with radiation exposure, may provide
a more holistic picture of the tumour and allows more frequent patient moni-
toring. However, an important feature and challenge in the analysis of cfDNA
is that the proportion of DNA of interest (foetal DNA or ctDNA) is often very
low, which implicates the need for methods with a level of detection down to,
and even below, a VAF of 0.01% (Fox et al., 2014).
A related example with similar demands and applications to those for
ctDNA, is the analysis of minimal/measurable residual disease (MRD) in leu-
kaemia. In MRD analysis, liquid samples from bone marrow or blood are
collected, but instead of the plasma, the leukocytes are analysed for the pres-
ence of low amounts of leukaemic cells. By utilising leukaemia-speciﬁc genetic
aberrations, the number of leukaemic cells can be inferred from the sequencing
data. The consensus requirement for MRD methods in acute myeloid leukaemia
(AML), the disease in focus in Paper II and III, is that they should be able to
detect leukaemic cells down to 0.1% (Schuurhuis et al., 2018), but even lower
levels are desirable.
The error proﬁle
To meet the resolution requirements for the described applications, there is
a need for very sensitive methods. To be able to use sequencing data, the
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depth must be increased, which can be achieved by targeting fewer and shorter
genomic regions than in exome sequencing, but instead sequence those to a
depth in the order of 100,000 or even higher. However, error rates up to 1%,
which have been reported for Illumina sequencing, the most commonly used
sequencing technique, still impose a challenge (Schirmer et al., 2016).
In targeted deep sequencing, a small part of the genome containing the
position(s) of interest is ﬁrst singled out and ampliﬁed by polymerase chain
reaction (PCR). In this process, the genomic material from the cells in the
sample is extracted and then targeted by PCR primers speciﬁcally designed
to only bind to the genomic region of interest. Starting at the attached PCR
primer, a copy of the desired part is built by elongating the new chain with
complementary nucleotides. The resulting DNA fragments are then further
ampliﬁed in additional PCR cycles. The DNA fragments are also prepared for
the subsequent sequencing through incorporation of, for example, sequencing
adapters and the index. The ampliﬁed fragments are then sequenced to a high
depth, typically generating 105 − 106 reads.
As described in Chapter 1, errors are introduced both in the sample prepa-
ration and during the actual sequencing (Olson et al., 2015). The use of PCR
in the sample preparation means that indicates nucleotides may be incorpo-
rated. This create errors that are already present before the DNA fragments
enter the sequencing machine and hence cannot be corrected for using the base
quality scores that are assigned to each base during sequencing. In contrast,
the well-known property that sequencing errors occur more often at the ends
of reads is attributed to the accumulation of phasing and pre-phasing in the
sequencing-by-synthesis method used in Illumina sequencing, and can thus be
reﬂected in the base quality scores (Schirmer et al., 2015). Other examples
of error causes in Illumina sequencing are the incorporation of incorrect nu-
cleotides during the sequencing-by-synthesis process and incorrect base-calling
when interpreting the ﬂuorescent signals.
The errors introduced during sample preparation and sequencing come in
diﬀerent forms. Some errors appear independently of the underlying sequence.
There are, however, also errors that are highly dependent on the nucleotide
context and, thus, are much more common in certain genomic positions. For
example, it has been shown that an elevated error rate is associated with the
preceding motif "GG" (Schirmer et al., 2016). There are discrepant results
regarding how well the assigned base quality scores actually characterise the
errors introduced during sequencing (Kozich et al., 2013; Schirmer et al., 2015).
Nevertheless, it can be concluded that bioinformatical approaches to remove
or correct error-prone reads or parts of reads based on quality scores help in
reducing the overall error rates. Schirmer et al. (2016) showed that for their
data, produced using a variety of sequencing platforms and sample preparation
methods, on average 69% of the errors could be removed by methods utilising
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quality scores. However, the elevated error rates associated with speciﬁc motifs
(i.e., nucleotide patterns) persisted. It was further shown that the systematic
bias in error rate diﬀered between sample preparation methods and sequencing
platforms. Thus, the error rates in the sequencing data typically vary system-
atically between diﬀerent genomic positions, and the patterns are speciﬁc to
each experimental setup. The systematic biases in error rates will hereafter be
denoted as position-speciﬁc errors.
Another source of errors in targeted deep sequencing originates from the
practice of multiplexing, i.e., to sequence several diﬀerent samples in the same
sequencing run. To distinguish between the samples, a speciﬁc index is given
to each sample by including the same short piece of DNA in all fragments
originating from that sample. Mis-assignments of reads due to for example
errors in the sequencing of the index or in the cluster separation lead to carry-
over between samples analysed in the same run and potentially elevated error
rates (Bartram et al., 2016).
Unique molecular identiﬁers
Diﬀerent experimental techniques have been developed to reduce the error rates
or provide means of correcting for errors, among which one strategy is the use
of unique molecular identiﬁers (UMIs) (Chaudhary and Wesemann, 2018). In
targeted deep sequencing, each DNA fragment is ampliﬁed during the sample
preparation and, due to the large depth, several of these copies are sequenced,
resulting in multiple reads originating from the same DNA fragment. In exome
sequencing, reading one of the original DNA fragments multiple times is not
desirable, as discussed in section 3.1, and copies are marked as duplicated
reads and excluded. In deep sequencing, sequenced copies can instead be used
to correct for errors that are introduced during the sequencing-by-synthesis
procedure or even late in the PCR ampliﬁcation during the sample preparation,
hence only aﬀecting some of the copies.
A requirement for error correction is that it can be inferred which reads
originate from the same original DNA fragment. This is something that can be
solved by attaching a UMI to each DNA fragment before ampliﬁcation. Then, a
consensus read can be inferred from all reads carrying the same UMI, ignoring
discrepancies that only occur in some of the reads. Although the technique
thus has the ability to reduce the error levels, a number of factors can impede
an accurate analysis. For example, to obtain a representative result, tagging
of the original fragments need to be uniform and eﬃcient, and the tags should
not give rise to bias in the PCR ampliﬁcation. Both factors have been reported
to be challenging (Kou et al., 2016). Additionally, the UMIs themselves can
be aﬀected by PCR errors, making it more diﬃcult to determine which reads
should be grouped together.
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Identiﬁcation of low frequency mutations
To identify low frequency mutations in deep sequencing data, the error struc-
ture must be taken into account. The existence of position-speciﬁc errors has
been considered in various variant calling methods. One strategy used for
exome sequencing data and somatic mutations was described in section 3.3.
There, a set of other samples, sequenced under similar conditions but believed
not to contain a mutation at the position of interest, were used to reveal posi-
tions with elevated error rates and hence point out potential artefacts in the list
of candidate somatic mutations. For targeted deep sequencing, it is possible to
infer position-speciﬁc error rates from a single control sample since the larger
depth provides a higher resolution. One example where this is utilised is the
somatic variant calling tool deepSNV.
In deepSNV, a tumour sample is compared with a control sample, and each
considered position is tested for diﬀerences in the rate of variant nucleotides
(Gerstung et al., 2012). The primary aim of the analysis is thus to determine
whether somatic mutations are present. For each position i, the counts of the
observed nucleotides in the control sample are modelled by a beta-binomial dis-
tribution. The beta distribution is parameterised by the mean error rate for the
position (qi) and an overdispersion parameter. The overdispersion parameter
is assumed to be the same for all positions in the sequenced fragments and in-
cluded to allow for extra variability in addition to the binomial one. Similarly,
the counts in the tumour sample are modelled by a beta-binomial distribution,
but the mean parameter in the beta distribution now includes both the mean
error rate and the frequency of a potential mutation (pi = qi+ f). With a like-
lihood ratio test statistic the alternative hypothesis that a mutation is present
(pi > qi) is tested against the null hypothesis of no mutation (pi = qi). The
overdispersion parameter in the likelihoods is estimated from two samples (con-
trol and tumour), assuming that the null hypothesis is true for all positions.
The test is applied to each strand separately, making it possible to consider
diﬀerent error rates depending on the sequencing direction.
Speciﬁc statistical methods for data generated by experimental techniques
using UMIs have been developed. See for example Xu (2018) for an overview
of such methods.
4.2 Using sequencing to quantify MRD levels in
leukaemia
In MRD analysis, the aim is to detect and quantify residual leukaemic cells in
bone marrow or blood samples during or after the treatment, in order to mon-
itor the treatment eﬀect or detect relapses at an early stage (Ravandi et al.,
2018). The task of distinguishing and quantifying the leukaemic cells can be
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solved in diﬀerent ways. Examples include identiﬁcation with ﬂow cytometry,
which is based on the patterns of expressed proteins at the cell membrane, or
quantifying fusion gene transcripts in cases where such an aberration is present
(Ommen, 2016). In Paper II and III, a personalised method for MRD analysis in
acute myeloid leukaemia (AML) using sequencing data and leukaemia-speciﬁc
mutations was developed and evaluated. The idea is to deﬁne each patients
proﬁle of somatic mutations at diagnosis and determine which of the muta-
tions are likely to be present in all leukaemic cells. Then, these mutations are
proposed for utilisation as patient-speciﬁc markers in an MRD analysis using
targeted deep sequencing. However, as described above, for this to be a sensi-
tive and accurate method, the noise in the deep sequencing data must remain
low. Therefore, speciﬁc means were taken to reduce the overall error levels.
Errors arising from carry-over between samples analysed in the same run
were considered. As described above, when performing deep sequencing, mul-
tiple samples are typically processed simultaneously. This is possible due to
sample indexing and increases the eﬃciency of the method but also introduces
the risk of errors in assignments and therefore noise in the data. This can be
a substantial problem if samples with the same mutation in diﬀerent variant
allele frequency levels are sequenced together. To reduce such errors, a number
of steps were taken. For example, dual unique indexing instead of single index-
ing was utilised and shown to reduce the carry-over by 10-fold. Additionally,
no mismatches were allowed for in the identiﬁcation of the index, as opposed to
the default procedure where one mismatch is accepted. For more details about
the means to reduce sample carry-over, see Paper III.
Furthermore, paired-end sequencing provided the possibility of reducing
errors by merging overlapping reads. This process was performed with the
software PEAR (Zhang et al., 2014). In the presence of an overlap at a position
and diﬀerences in the two called bases, the one with the highest quality score
is incorporated in the merged read. Therefore, PEAR is able to correct for
sequencing errors that are reﬂected in the quality score. The merged reads
were then quality ﬁltered to remove reads with a low mean sequencing quality.
Additionally, the merged reads were mapped to the reference genome, and
only reads with a perfect match to the reference sequence in a ten-base region
surrounding the analysed position were kept. Both these procedures, quality
ﬁltering and not allowing for sequencing errors in the surrounding, remove reads
that are generally error prone and hence reduce the overall error level.
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4.3 A statistical model for assessment of the
MRD level
To take the remaining errors into account and acknowledge that error rates dif-
fers between positions, a statistical model with position-speciﬁc error correction
was developed. Assume that for each chosen leukaemia-speciﬁc mutation, the
variant allele is denoted by M and the underlying VAF in the patient sample is
denoted by f . After sequencing and applying a number of pre-processing steps
(see section 4.2), the counts of the variant allele, yM , and the total number of
allele counts, N (i.e., the sequencing depth), were recorded for each sample.
Assuming a ﬁxed N and that fragments are picked at random and indepen-
dently for sequencing, the variant allele counts within a sequencing experiment
for a speciﬁc sample follows a binomial distribution. Since N is large (typically
between 105 and 106), a normal approximation to the binomial distribution
was applied. Hence
YM ∼ norm(NpM , NpM (1− pM )),
where pM denotes the probability of observing the variant allele. Furthermore,
assume that the probability pM follows
pM = f + ,
where  denotes the probability of observing a variant allele due to errors in
the sequencing process. The error probability  was estimated by sequencing
a reference sample that did not contain the variant allele and using the same
protocol as for the patient sample. Note that  includes sequence speciﬁc errors,
i.e. errors that depends on the sequence context of the chosen leukaemia-speciﬁc
mutation, and hence a reference analysed at the exact same position was used
in each case. The variant allele counts and the sequencing depth observed in
the reference sample were denoted yrefM and N
ref , respectively, and hence, the
error probability estimate was yrefM /N
ref . Similarly, the observed VAF in the
patient sample, yM/N , was used to estimate pM . Thus, an estimator fˆ for the
underlying VAF in the patient sample was deﬁned as
fˆ =
YM
N
− Y
ref
M
Nref
.
The estimate of f is also referred to as the error corrected variant allele fre-
quency (VAFEC).
The variance of fˆ was divided into two components. The ﬁrst one, denoted
σ21 , was the sample speciﬁc variability that follows from the random sequencing
of DNA fragments. It was calculated by
σ21 =
pM (1− pM )
N
+
 (1− )
Nref
.
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The second component captures variability in fˆ between samples that were not
yet accounted for, arising from factors such as discrepancies in sample handling,
quality and preparation as well as diﬀerences in error rates between sequencing
runs. It was modelled as an additive variance component, denoted σ22 , and it
was assumed to be common across samples with the same underlying VAF f
and run under the same conditions.
Thus, the distribution of fˆ was modelled as
fˆ ∼ norm(f, σ21 + σ22),
where f and σ21 are sample speciﬁc, while σ22 is common for all samples.
For estimation of the sample speciﬁc parameters in sample i, let yM,i denote
the observed number of variant alleles and Ni the sequencing depth. Let the
corresponding values for a reference sample, with the same leukaemia-speciﬁc
mutation as in sample i, be denoted yrefM,i and N
ref
i . The estimated value of
the underlying VAF fi in sample i (the estimate also referred to as VAFEC)
was calculated as
fˆi = VAFECi =
yM,i
Ni
− y
ref
M,i
Nrefi
.
The ﬁrst variance component, σ21,i, is unique for each sample and depends
on the underlying VAF, the error probability and the sequencing depth. For
sample i, σ21,i was estimated as
σˆ21,i =
yM,i
Ni
(
1− yM,i
Ni
)
1
Ni
+
yrefM,i
Nrefi
(
1− y
ref
M,i
Nrefi
)
1
Nrefi
.
The second variance component, corresponding to the between sample vari-
ability, σ22 , can be estimated from a set of n samples that are run under similar
conditions and with the same underlying VAF f . Estimation of σ22 was per-
formed using maximum likelihood, which gives the following equation
n∑
i=1
1
(σˆ21,i + σˆ
2
2)
−
n∑
i=1
(fˆi − f)2
(σˆ21,i + σˆ
2
2)
2
= 0.
The estimate σˆ22 was calculated by numerical maximisation. The value for f
was either estimated from the mean of fˆi:s or set to a known value.
In the evaluation of the proposed MRD analysis method utilising the model
described above, the coeﬃcient of variation and limit of detection was calcu-
lated by estimating the model parameters under speciﬁc experimental settings.
See the Statistical Analysis paragraph in the Materials and Methods section in
Paper III for a description of how this was performed.
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Here, we proposed a method to determine the frequency of a leukaemia-
speciﬁc mutation through an estimator based on the diﬀerence in observed
VAF between the patient sample and a reference sample. The reference sample
was used to estimate the error level. By having one reference sample per sought
mutation and considering the exact same genomic position as for the mutation,
position-speciﬁc errors were taken into account. The counts of the variant allele
within a sequencing experiment were assumed to follow a binomial distribution
and, hence, to vary depending on the probability of observing the variant allele,
which includes the position-speciﬁc error rate, and the sequencing depth. This
was taken into consideration in a ﬁrst variance component, σ21 . As opposed
to the deepSNV method (Gerstung et al., 2012) described in section 4.1, a
normal approximation was made to the binomial distribution when modelling
the observed counts. Additionally, instead of incorporating between-sample
variability through a beta-binomial distribution we chose to add a second ﬁxed
component, σ22 , to the variance. Thus, the second variance component was
assumed to be independent of the sequencing depth and the position-speciﬁc
error level. The latter factor is, however, conﬁned to a low value, as mutations
with an estimated error level above 0.05% were evaluated as unsuitable as MRD
markers and excluded from the analysis. Estimation of the second component
should be performed based on samples with the same f (i.e., frequency of the
mutation in the sample) and is then valid only for this level of f .
In the proposed model, the between sample variability, captured by the
second variance component, is estimated from a set of samples. This is in
contrast to deepSNV, in which an overdispersion parameter is estimated from
only one pair of tumour and reference samples under the somewhat question-
able assumption that the overdispersion is identical along the read. Note that
the choice of samples used to estimate σ22 determines which between-sample
variability is included. For example, one can choose to only include samples
where one speciﬁc position is analysed. Alternatively, as we did when esti-
mating the limit of detection, one can include samples where many diﬀerent
positions are analysed and, hence, also capture the between-marker variability.
We have not taken the strand explicitly into account in the model, neither set
a cut-oﬀ for the base quality score. We believe that both the requirement for
perfect matches to the reference in an area surrounding the position of interest,
and the merging of reads, lead to the inclusion of few bases of low quality in
the analysis. This remains, however, to be conﬁrmed. Finally, the proposed
method in Paper III is formulated with the prerequisite that the position of
the mutation is known. However, it should be straight-forward to generalise
the method to search for new mutations, with the limitation associated with
all deep sequencing that the region to target must be decided. Additionally,
the PCR primers were designed to have the mutation of interest in the middle
of the fragment and to have substantial overlap between the paired reads to
27
Chapter 4. Sensitive detection of mutations using targeted deep sequencing
lower the general error rate. Thus, one should keep in mind that the sensitivity
and speciﬁcity may change if searching for mutations located near the ends of
the reads or using reads with less overlap between read pairs.
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5.1 Paper I – Malignant pheochromocytomas/
paragangliomas harbour mutations in trans-
port and cell adhesion genes
Pheochromocytoma (PCC) and paraganglioma (PGL) are rare neuroendocrine
tumours located in the adrenal medulla or extra-adrenal paraganglia. Just over
10% of the patients with a primary PCC/PGL tumour develop malignant dis-
ease (Goldstein et al., 1999). The prognosis for patients with malignant disease
is poor, and metastases may occur several years after removing the primary tu-
mour. Thus, long-term surveillance of PCC/PGL patients is required. This is
emphasised by the observation that although some factors that may indicate
a higher risk of future malignancy are known, there is currently no reliable
way to predict if a primary tumour will metastasise. Inherited mutations that
predispose individuals to PCC/PGL have been characterised, but less is known
about additional somatic events leading to tumour progression and malignancy.
In Paper I, the aim was to investigate somatic mutations in benign and
malignant PCC/PGL tumours and to identify somatic mutations that con-
tribute to the malignant transformation. Exome-sequencing of paired samples
(normal–tumour) from four patients with benign and ﬁve patients with ma-
lignant tumours was performed. Two biological replicates were collected from
each tumour, one from fresh-frozen (SF) and one from formalin-ﬁxed paraﬃn
embedded (FFPE) material. In exome sequencing, DNA fragments from the
protein-coding part of the genome are sequenced. The resulting reads are then
aligned to the human reference genome to identify its original location. Both
mutations and sequencing errors will be displayed as mismatches between the
reads and the reference genome. The statistical challenge is then to identify
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which genomic positions truly have mutations, in contrast to those where the
discrepancies only represent noise. An additional diﬃculty in searching for so-
matic mutations in contrast to inherited ones is that the variant allele frequency
might be low, due to a potential heterogeneity of the tumour or contamination
from normal cells. The ﬁrst step in the bioinformatical and statistical analysis
is to pre-process the data, with the aim to correct, or at least compensate, for
errors in the data. The raw sequencing data was quality-trimmed, aligned to
the human reference genome, marked for duplicates, realigned patient-wise and
base-recalibrated. For the subsequent identiﬁcation of candidate somatic muta-
tions, a method called MuTect was applied, which includes a Bayesian classiﬁer
that is designed to also be able to capture low-frequency mutations (Cibulskis
et al., 2013). This procedure was followed by diﬀerent ﬁlters to enhance speci-
ﬁcity and account for errors not captured in MuTect’s statistical model, and
functional annotation. For details about the pre-processing, identiﬁcation of
somatic mutations, ﬁltering and annotation, see Chapter 3.
The resulting landscape of somatic mutations included 225 unique muta-
tions, located in 215 genes, with a median VAF of 0.27 for SF samples and
0.29 for FFPE samples. In Figure 5.1a, the VAF for each somatic mutation is
shown, grouped per sample. The average mutation rate per sample was 0.54
mutations/megabase, placing the mutation rate of PCC/PGL tumours in the
lower range compared with other cancer types. A signiﬁcantly higher rate of
mutations in malignant tumours in comparison to benign ones was observed
(Figure 5.1b). Four genes had somatic mutations in more than one patient:
HRAS, MYCN, MYO5B and VCL. Mutations in HRAS were found in benign
sporadic cases, similar to the ﬁndings in previous studies examining PCC/PGL.
Recurrent mutations in MYCN, MYO5B and VCL are, however, novel ﬁnd-
ings in PCC/PGL and were exclusively found in malignant PGL cases. Out
of these three mutations, MYCN is a previously known oncogene. MYO5B
and VCL have functions related to cell migration, an important mechanism for
malignant potential in tumours. When screening publicly available PCC/PGL
datasets, three additional MYO5B mutations were found, two in patients with
malignant disease and one in a tumour displaying pathological risk factors for
malignancy. Altogether, the study contributes to the search for a set of genetic
markers that predicts malignancy, which could aid in treatment and surveil-
lance decisions and beneﬁt the outcome for patients harbouring tumours with
high malignant potential.
Furthermore, the overlap between SF and FFPE samples was in general
high, with an average of 58% of the mutations found in SF samples also present
in corresponding FFPE samples. This result exempliﬁes the utility of FFPE
material in exome-sequencing studies for somatic mutations. Additionally, the
unique mutations identiﬁed in each sample conﬁrm the heterogeneity of tu-
mours and show that biological replicates contribute to a more complete picture
30
5.2. Paper II
benign samples
x
x
x
x
x
x
x
x x
x
x
x
x
x
x
x
x
x
x
x
x
x
CPN1
 
CPN8
 
CPN7
 
CPN6
 
CPN4
 
CPN3
 
CPN9
 
CPN5
 
CPN2
 
Va
ria
nt
 a
lle
le
 fr
eq
ue
nc
y
0
0.2
0.4
0.6
0.8
1.0
 
Va
ria
nt
 a
lle
le
 fr
eq
ue
nc
y
0
0.2
0.4
0.6
0.8
1.0
 
p-value = 0.0009
40
30
20
10
0
p-value = 0.02
malignant benign malignant
SF tissue FFPE tissue
N
um
be
r o
f m
ut
at
io
ns
benign
malignant samples
A
B
Figure 5.1: The landscape of somatic mutations in PCL/PGL. In A), the VAFs for
somatic mutations in four benign cases and ﬁve malignant cases are shown. Mu-
tations in SF samples are displayed in black, mutations in FFPE samples in grey.
Dots represent substitutions, and crosses represent small insertions/deletions. The
observed distribution of VAF in SF samples is shown to the right. In B), the mean
number of mutations per sample is shown. There was a signiﬁcant diﬀerence in the
mutation rate between benign and malignant samples.
of the landscape of somatic mutations.
5.2 Paper II – Patient-tailored analysis of min-
imal residual disease in acute myeloid leu-
kaemia using next generation sequencing
In leukaemia, the white blood cells are aﬀected, and in contrast to solid tu-
mours, the cancer cells are naturally mixed with normal cells. The most com-
mon form in adults is acute myeloid leukaemia (AML). The primary treatment
is induction chemotherapy with the aim of achieving remission, i.e., no signs of
the disease, followed by consolidation with chemotherapy with or without stem
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cell transplantation. In the risk stratiﬁcation of patients and decisions about
the treatment intensity, early response to treatment is one of the most impor-
tant factors. This is monitored during treatment by measuring the amount of
remaining leukaemic cells, denoted the analysis of minimal/measurable resid-
ual disease (MRD). To perform MRD analysis as surveillance for patients in
remission is becoming increasingly used for early detection of relapses (Ravandi
et al., 2018). Today, multiparameter ﬂow cytometry (MFC) is the most com-
monly used method for MRD analysis evaluating the response to treatment. It
utilises the immunophenotype of the leukaemic cells, i.e., the set of expressed
proteins at the cell surface. The technique is applicable in a large proportion of
patients (∼ 90%), but it has several disadvantages, including a potential shift
in the immunophenotype, which can lead to false negative results and lowers
its ability to predict relapses (Ommen, 2016). Instead, genetic aberrations in
the leukaemic cells can be utilised for MRD analysis. However, the genetic
heterogeneity of the disease means that there is no limited set of recurrent ge-
netic variants that can be used for all patients (Shen et al., 2011). Therefore,
patient-tailored approaches are required to utilise each patient’s speciﬁc genetic
changes in leukaemic cells as markers.
In the study described in Paper II, the aim was to identify leukaemia-
speciﬁc mutations in patients with AML and evaluate their suitability for
patient-tailored MRD analysis. To obtain the proﬁles of leukaemia-speciﬁc
mutations in individual AML patients, leukaemic cells and normal lympho-
cytes from 17 patients were isolated using ﬂuorescence activated cell sorting.
The two fractions from each patient were then exome-sequenced separately
and analysed in a paired design to decide which mutations existed only in
the leukaemic cells. After data pre-processing, the identiﬁcation of candidate
leukaemia-speciﬁc mutations and ﬁltering to remove potential false positives,
see Chapter 3 for details, a total of 262 leukaemia-speciﬁc SNVs and indels
were found. To avoid false negative results due to subclonality, we want candi-
date mutations to be present in all leukaemic cells to be classiﬁed as suitable
for MRD analysis. The majority of the identiﬁed mutations had a variant
allele frequency (VAF) of approximately 0.5, corresponding to being present
as heterozygous mutations in all leukaemic cells (Figure 5.2a). The random
selection of DNA fragments for sequencing give rise to binomial distributed
variant allele counts, and observed VAFs are therefore expected to ﬂuctuate
around 0.5, even if each mutation truly is heterozygous and present in all cells.
However, some mutations showed a VAF considerably lower than 0.5, which
could indicate that they were only present in a subset of the leukaemic cells. A
comparison of the observed VAF distribution to a simulated distribution was
conducted, taking the realised sequencing depths into account and assuming
heterozygosity for all mutations in the simulation (Figure 5.2b). Although the
results showed an overall correspondence, there was evidence that a portion of
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the observed mutations actually had a lower observed VAF than expected for
heterozygous mutations. To remove those mutations unlikely to be present in
all leukaemic cells, a 95% conﬁdence interval around the VAF of each mutation
was calculated based on the observed depth and utilising a normal approxima-
tion. Mutations where the interval was below 0.50 were excluded. In total, 191
leukaemia-speciﬁc mutations passed this ﬁltering step and were thus consid-
ered candidates for MRD analysis. All patients but one had MRD candidates
in their somatic mutation proﬁle (median 11 per case, range 0-25).
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Figure 5.2: The variant allele frequencies of the identiﬁed somatic mutations. In A),
the VAF for each mutation is displayed, divided by case. Dots represent substitutions
and crosses represent small insertions/deletions. A denotes adult AML cases, and C
indicates childhood AML cases. In B), the solid line shows the observed distribution of
VAF, while the dashed line shows the simulated observed distribution when assuming
all mutations to be heterozygous and present in all cells.
To detect the low frequencies of mutations that are desirable in MRD anal-
ysis, targeted deep sequencing, where a speciﬁc part of the genome is selected
and sequenced to a high depth, can be utilised. The technique was used on
follow-up samples from a patient with AML. Four mutations from the set of pre-
viously identiﬁed MRD candidates for the patient were analysed. The results
showed that this approach for MRD analysis was more sensitive than the stan-
dard MFC method. Furthermore, when the MFC method failed to correctly
capture a relapse after 10 months due to a change in immunophenotype for a
majority of the leukaemic cells, all four of the mutations were detected with
a high mutation load. Thus, targeted deep sequencing of the mutations, iden-
tiﬁed by exome sequencing of sorted leukaemic cells and lymphocytes, herein
successfully accomplished MRD quantiﬁcation. This approach could contribute
to making MRD analysis possible for all patients.
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5.3 Paper III – Accurate and sensitive analysis
of minimal residual disease in acute myeloid
leukaemia using deep sequencing of single
nucleotide variations
As described in the summary for Paper II, minimal/measurable residual disease
analysis is important in risk stratiﬁcation and monitoring of acute myeloid
leukaemia patients. In general, each patient has a number of somatic mutations
in his or her leukaemic cells, which may be used as markers in MRD analysis
and thus allow patient-tailored assays.
The aim of Paper III was to characterise and validate the use of targeted
deep sequencing of leukaemia-speciﬁc substitution mutations, identiﬁed by ex-
ome sequencing, for MRD analysis. The basic idea of deep sequencing is that
the proportion of reads having the leukaemia-speciﬁc variant allele, in contrast
to reads from the same region having the reference allele, contains quantitative
information about the level of leukaemic cells in the sample. The accuracy
of the quantitative information is, however, challenged by errors in the data.
Hence, a key aspect in using targeted deep sequencing of single nucleotide sub-
stitutions for MRD detection and quantiﬁcation purposes is to keep the level
of noise low to reach the consensus requirement for molecular MRD analysis of
being able to detect leukaemic cells down to the 0.1% level (Schuurhuis et al.,
2018). An additional aim is to develop an even more sensitive method, that is
able to quantify low levels of leukaemic cells. This achievement could enable
a more detailed evaluation of the results of treatment and contribute to the
detection of emerging relapses as early as possible.
To reduce the overall level of noise and thereby increase the sensitivity in
the assay, a number of considerations were made in the sample preparation
and bioinformatical processing of the data (see section 4.2). However, it is
known that sequencing errors in the MiSeq platform do not occur completely
randomly. The nucleotide context for a position inﬂuences its error rate, and
the three possible substitution errors for a position are not evenly distributed
(Schirmer et al., 2016). To be able to take the position-speciﬁc errors into
account, without making precedent general assumptions about the error struc-
ture, a reference sample for each leukaemia-speciﬁc mutation was sequenced
and used for adjustment of the variant allele frequency (VAF) estimate. That
is, an error corrected VAF (VAFEC) was calculated as the diﬀerence in VAF
between the sample of interest and a reference sample. In this way, a correction
was made for both general and sequence-speciﬁc errors. A statistical model for
the estimation with position-speciﬁc error correction was formulated. The vari-
ability of VAFEC was divided into two components, taking both within- and
between-sample variation into account. The ﬁrst variance component mod-
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els the sample-speciﬁc variability that follows from random sequencing of DNA
fragments. The second variance component corresponds to the between-sample
variability caused by factors such as discrepancies in sample handling and qual-
ity, preparation and error rates between sequencing runs. For details about the
statistical model, see section 4.3.
First, the eﬀect of the position-speciﬁc error correction was evaluated by
estimating the total variability in the assay with and without the use of a
reference sample. The sample standard deviation for 15 normal samples cor-
responding to 15 diﬀerent mutations was calculated. The value without using
the position-speciﬁc error correction was 0.0123%, as compared to a value of
0.0060% using VAFEC. Hence, the noise level was reduced by 51%, and it can
be concluded that the sensitivity of the method was substantially improved.
The precision and accuracy of the assay were then determined from DNA
samples with known levels of mutations, where each set of level (0.01% and 1%)
and mutation (four diﬀerent mutations) was sequenced in triplicates, and the
model parameters were estimated. The precision was evaluated by calculating
the coeﬃcient of variation (CV) for each set, resulting in a median value of
4.1% at VAF 1% and 13.3% at VAF 0.1%. The median relative bias at VAF
1% was 7.9%.
Figure 5.3: The limit of detection (LOD) as a function of sequencing depth. The LOD
was estimated to a value of 0.020% at a sequencing depth of 5.0× 105 (dotted line),
utilising 15 normal samples each sequenced for a diﬀerent mutation. The minimum
LOD, i.e., the value that can be reached in the absence of within-sample variability,
was estimated to be 0.0185% (dashed line).
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The limit of detection (LOD) was determined from 15 normal samples (i.e.
f = 0), each sequenced for a diﬀerent mutation, and calculated as the absolute
value of the mean VAFEC + 3 standard deviations. The limit of detection de-
pends on the sequencing depth through the within-sample variability captured
in the ﬁrst variance component σ21 , and hence, it is lower at a higher sequencing
depth (Figure 5.3). At a sequencing depth of 5.0×105, the LOD was estimated
to be 0.020%, corresponding to 1 cell in 2500 with a heterozygous mutation.
Raising the sequencing depth further only lowered the LOD marginally, and
the minimum value of the LOD was estimated to 0.0185%. The probability
of observing a VAFEC above the LOD at an underlying VAF in the patient of
f = 0.05%, at a sequencing depth of 5.0 × 105, was calculated to be >99.9%.
That is, if a sample contains at least 0.1% leukaemic cells with a heterozygous
mutation at the analysed position, the probability of detection with the assay
is greater than above 99.9%. For details about the calculations of CV, LOD
and probability, see the paragraph Statistical Analysis in the Materials and
Methods section in Paper III.
Figure 5.4: Comparison of determined MRD levels between targeted deep sequenc-
ing (y-axis) and MFC (x-axis). The lines shows the limit of detection at 0.020%
for deep sequencing and 0.1% for MFC. Neg denotes a value below the limit of de-
tection, LAIP denotes leukaemia-associated immunophenotype. Fifty-four determi-
nations showed consistent MRD assignment (31 MRD+ with both methods and 23
MRD- with both methods), while 16 determinations diﬀered (all those were MRD+
with deep sequencing and MRD- with MFC).
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Figure 5.5: Comparison between the use of deep sequencing and MFC for MRD
monitoring. In A), time series for a patient who relapsed is shown, where deep
sequencing showed the MRD+ status at the last time point before the relapse. In
B), time series for at patient that remained in remission after completion of therapy
is shown. D22 denotes day 22 after start of the induction course, and ind. denotes
induction. Filled circles indicates measurable levels, empty circles indicates a value
below the limit of detection.
The proposed method for MRD marker identiﬁcation at diagnosis and quan-
tiﬁcation during treatment was tested in 6 AML cases. In total, 34 bone
marrow samples were analysed for MRD levels with two or three leukaemia-
speciﬁc mutations utilised per sample. Concordant MRD assignment (MRD-
if VAFEC<LOD, otherwise MRD+) for all the mutations analysed in one sam-
ple was observed in 19 of 23 samples (3 mutations analysed) and in 10 of 12
samples (2 mutations analysed). For 27 of the samples, MRD analysis using
multiparameter ﬂow cytometry (MFC) had been performed as part of the clin-
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ical routine. In Figure 5.4, the levels determined with deep sequencing were
compared against the levels determined with MFC. An integrated assignment
of the MRD status for samples analysed with deep sequencing was deﬁned as a
sample being MRD+ if at least one mutation showed an MRD level above the
LOD and MRD- otherwise. When comparing the MRD status based on MFC
and deep sequencing, consistent results were observed in 18 out of 27 samples.
The remaining 9 samples were MRD+ with deep sequencing and MRD- with
MFC, and notably, no samples classiﬁed as MRD+ with MFC were failed to
be detected by deep sequencing (see Table 3 in Paper III). Hence, the deep
sequencing assay showed concordance with MFC but had higher sensitivity. In
Figure 5.5, time series for two patients with AML are shown, reporting the
results for MRD analysis using deep sequencing of leukaemia-speciﬁc muta-
tions and MFC at the same time points (6 time series in total are reported in
Paper III). Note that the patient in Figure 5.5a with relapse was determined
as MRD+ with deep sequencing after the second induction while MRD- using
MFC, indicating that the higher sensitivity of the deep sequencing assay might
be of prognostic value. The speciﬁcity of the deep sequencing assay was es-
timated to 97% by analysing 10 follow-up samples from 5 AML patients for
3 mutations that were not detected in their genomes, but instead present as
leukaemia-speciﬁc mutations in another AML case.
In conclusion, patient-tailored targeted deep sequencing with correction for
position-speciﬁc errors, and utilising a statistical model that takes both within-
and between-sample variability into account, was shown to be able to achieve
a low limit of detection, estimated herein as 0.020%. The assay thereby had
superior sensitivity than ordinary MFC-MRD analysis, and it also showed high
speciﬁcity. Thus, the introduction of this method in clinical care could con-
tribute to providing virtually all AML patient with a sensitive and accurate
method for MRD monitoring.
5.4 Paper IV – miRNA proﬁling of small intesti-
nal neuroendocrine tumours deﬁnes novel
molecular subtypes and identiﬁes miR-375 as
a biomarker of patient survival
Small intestinal neuroendocrine tumours (siNETs) are hormone-producing tu-
mours localised in the small intestinal, with a low proliferation rate and grade,
meaning that the primary tumour often grows slowly and shows resemblance to
normal cells. However, the diagnosis of siNETs is often not made until metas-
tases have developed, and the 5-year survival for patients with liver metastases
is poor. The individual prognosis is, however, highly variable and diﬃcult
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to predict. Thus, there is a need to better understand the molecular mech-
anisms that drive progression and, hence, to identify molecular subgroups of
the tumours and biomarkers for prognosis, disease progression and response
to treatments. Changes in gene expression are known to be an essential com-
ponent of cancer development. One form of transcriptional regulator is the
microRNAs (miRNAs), which are short non-coding RNA stretches that bind
to mRNA and thereby suppress translation and increase mRNA-degradation.
One miRNA can regulate several diﬀerent mRNAs, and they can contribute to
tumour development by targeting genes involved in molecular mechanisms of
cancer, e.g., cell cycle control and invasion.
In Paper IV, the aim was to determine the miRNA proﬁle of siNETs and
search for miRNA-based molecular subgroups and biomarkers. The miRNA
expression was determined by one-colour microarrays in 42 tumours from 37
patients, all with a documented survival time and with well-characterised clini-
copathological factors. In addition, 6 samples from normal small intestinal mu-
cosa were analysed. Each microarray contained 866 human and 89 human viral
miRNAs, measured by 2-4 diﬀerent probes per miRNA. After quality control of
the arrays, background correction using the normexp method was performed to
remove diﬀerences in the ambient signal (Ritchie et al., 2007). Then, to enable
comparison of the expression values between arrays, normalisation to remove
systematic trends in the data that do not depend on the biology but rather on
technical aspects was applied over all arrays using the quantile-quantile method
(Bolstad et al., 2003). Spots measuring the same probe (4-8 spots per probe)
were then merged on each array by taking an average of the normalised values.
Figure 5.6: Hierarchical clustering of 42 tumour biopsies and 6 normal samples. Three
major clusters of tumours are formed, one with primary tumours (Cluster P), one
smaller cluster with metastases only (Cluster M1) and one larger cluster with almost
exclusively metastases (Cluster M2). N denotes normal small intestinal samples, P
denotes primary tumours, M denotes metastases and the letters a-e indicates tumours
from the same patient (one primary tumour and one metastasis from each patient).
Clustering of the miRNA proﬁles of all tumours and the normal samples
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was performed using unsupervised hierarchical clustering with complete link-
age and the Euclidean distance as the metric. Three major clusters were ob-
served for the tumours, one containing only primary tumours, and two clusters
(denoted M1 and M2) consisting almost exclusively of metastases (Figure 5.6).
Five patients contributed both primary tumours and metastases, and all paired
samples were separated into diﬀerent clusters. The clustering was repeated for
metastases only (26 tumours), showing the same subgrouping. Test of associa-
tion between clusters and the clinicopathological characteristics of the patients
showed that the tumours in cluster M1 and M2 signiﬁcantly diﬀered in prolif-
eration rate, as measured by tumour grade and Ki67 index, and chromosomal
copy number (see Table 2 in Paper IV). Additionally, the patients in cluster
Figure 5.7: Kaplan-Meyer estimates showing the diﬀerence in survival times between
patients with tumours in cluster M1 and those with tumours in cluster M2. Patients
in cluster 1 had signiﬁcantly shorter survival time (log-rank test, p-value 0.029).
M1 had signiﬁcantly shorter overall survival (Figure 5.7). Using a Cox propor-
tional hazards model, adjusting for age and gender and calculating the survival
time from the date of surgery, the hazard ratio was estimated to 3.4 (p-value
0.018).
To identify and rank diﬀerentially expressed miRNA between two groups of
samples, the moderated t-statics was used (Smyth, 2004). In principle, for each
miRNA the mean diﬀerence in expression between the groups was calculated
and then divided by its standard error. When estimating the standard error,
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using the moderated t-statics means that information is shared between all
miRNAs using a common prior distribution instead of, as for the ordinary t-
statistic, only using data from the miRNA in question. The p-values in each
comparison were adjusted for multiple testing using Benjamini-Hochberg false
discovery rate, and tests with adjusted p-values below 0.05 were considered
signiﬁcant. The latter means that the expected rate of false positives among the
signiﬁcant miRNAs is estimated to be at most 5%. The analysis of diﬀerentially
expressed miRNA between cluster M1 and M2 identiﬁed a number of miRNA
previously reported to be associated with malignant behaviour of tumours. For
example, miR-1246 and miR-663a, which are known to have oncogenic eﬀects,
had elevated levels in the cluster with higher proliferation rate and shorter
overall survival (M1), while miR-488-3p, shown to be a tumour suppressor in
gastric cancer, had reduced levels in the same cluster.
Diﬀerential expression was also examined between groups of metastases
based on the proliferation rate (measured as the Ki67 index) and then based
on whether the metastases had a gain of chromosome 14. Furthermore, the
relationship between miRNA expression and tumour progression was investi-
gated in a paired analysis with both primary tumours and metastases from 5
patients. For signiﬁcantly regulated miRNAs and subsequent miRNA target
scan followed by pathway analysis, see the Results section in Paper IV.
Comparison of miRNA expression between normal small intestinal mucosa
and siNETs showed that miR-375 was upregulated in tumours. Interestingly,
when searching for miRNA associated with survival time in metastases, down-
regulation of miR-375 was the top candidate (adjusted p-value 0.093). These
ﬁndings were further investigated in situ by utilising a tissue microarray from
an independent cohort of siNETs where in situ hybridisation with a miR-375
speciﬁc probe was performed. Expression of miR-375 was found in 91% of
the biopsies (578/635), but only in the enteroendocrine cells located in the
crypt and on the villus in normal small intestinal mucosa. Patients with higher
expression of miR-375 (score 3) in liver metastases had signiﬁcantly longer
survival times than those with lower expression of miR-375 (score 0, 1 or 2)
(Figure 5.8). When applying a Cox proportional hazards model, adjusting for
age and gender, the hazard was a third for the patients with high versus low
expression of miR-375 (HR: 0.32, p-value 0.026). A similar trend was observed
in lymph node metastases, although it was not signiﬁcant. These results are in
accordance with other studies identifying miR-375 as a tumour suppressor and
biomarker of prognosis. However, miR-375 has also been assigned oncogenic
eﬀects in a few cancer types, and its functional role in siNETs need to be further
investigated and established.
To summarise, clinically relevant novel subgroups of metastatic siNETs were
identiﬁed based on miRNA expression proﬁles. In the search for biomarkers
in siNETs, downregulation of miR-375 showed an association with a shorter
41
Chapter 5. Summary of papers
Figure 5.8: Kaplan-Meyer estimates showing the diﬀerence in survival times between
patients with liver metastases with high expression of miR-375 (score 3) and low
expression of miR-375 (score 0-2), as measured by in situ hybridisation on a tissue
microarray. Patients with lower expression of miR-375 had a signiﬁcantly shorter
survival time (log-rank test, p-value 0.016).
survival time and is suggested for further evaluation as a prognostic biomarker.
5.5 Paper V - A hierarchical Bayesian model for
assessing diﬀerential nucleotide composition
between metagenomes
In metagenomics, microbial communities are analysed by sequencing their ge-
netic material. Up until recently, the main interest of metagenomic studies have
been the composition of species and biological functions and their variability
between diﬀerent experimental conditions. However, the increasing resolution
in the data enables the analysis of changes in nucleotide composition, something
that is crucial in order to understand the cause of phenotypic diﬀerences be-
tween microbial communities. For example, alteration of only a few nucleotides
is enough to make many bacteria highly resistant to antibiotic treatment (Blair
et al., 2015). The challenges in performing analysis of nucleotide diﬀerences
in sequencing data include the large dimensionality of the data, with many
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nucleotide sites to analyse, and the often high levels of biological and technical
variability. For instance, samples from the same condition can vary consider-
ably due to factors such as lifestyle and sex if studying the human microbiota,
or temperature and available nutrients if studying environmental samples (Yat-
sunenko et al., 2012).
In paper V, the aim is to detect diﬀerences at nucleotide level between
groups of metagenomes sampled from diﬀerent experimental conditions. In
particular, assuming that the average nucleotide proportions for a genomic
position i in each condition respectively are described by the vectors τi1 =
[τAi1 , τ
C
i1 , τ
G
i1 , τ
T
i1] and τi2 = [τAi2 , τCi2 , τGi2 , τTi2], the aim is to identify the positions
where τi1 and τi2 diﬀer. We propose a Bayesian hierarchical model, that ac-
counts for both within- and between-sample variability and utilises a shrinkage
approach in the variance estimation.
Assume that each sample have been sequenced separately, and that vectors
of counts of the four diﬀerent nucleotides A, C, G and T are observed, i.e., let
xijk = [x
A
ijk, x
C
ijk, x
G
ijk, x
T
ijk],
where i = 1, . . . , n denotes the position, j ∈ {1, 2} the condition and k =
1, . . . ,mj the sample. Assuming that the DNA fragments are picked randomly
and independently for sequencing, the vector of counts is modeled with a multi-
nomial distribution with parameters pijk, denoting the nucleotide composition
vector (with elements summing to one), and Nijk, denoting the sequencing
depth. To take the biological and technical variability between samples into
account, pijk is assumed to follow a Dirichlet distribution with parameters τijk,
the average nucleotide composition, and Ai, controlling the amount of extra
variability compared to a standard multinomial distribution. Thus, the uncon-
ditional distribution of Xijk follows a Dirichlet-multinomial distribution, where
the variance is
Var[X lijk|Ai, τij ] = Nijkτ lij(1− τ lij)
(
1 +
Nijk − 1
Aij + 1
)
.
As a result, the variance has one part that is due to the random sampling of
DNA fragments within a sample, and a second part that captures the between-
sample variability. We apply a shrinkage approach where we let A′i = 1/Ai
follow a common prior distribution, that does not depend on the position. The
model was ﬁt to data using Markov Chain Monte Carlo (MCMC) simulations
with the Gibbs sampler algorithm.
In order to rank the positions according to the likeliness of a diﬀerence in
genetic composition, we ﬁrst let δi be the diﬀerence in nucleotide composition,
i.e., δi = τi1 − τi2. A score Di, based on measuring the distance from the
posterior mean of δi to zero, while correcting for the uncertainty, is deﬁned as
Di = μδiΣ
−
δi
μTδi ,
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where μδi and Σδi denotes the expected value and the covariance matrix of the
posterior distribution of δi, respectively.
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Figure 5.9: Posterior median values for the overdispersion parameter A′i (log scale).
The group size was set to 5, while the sequencing depth was varied between samples
but with a mean sequencing depth that was in a) set to 100, in b) set to 1000 and in
c) set to 10,000. The scatter plots show a comparison between the estimated and the
true values (full model in pink, model without shrinkage in blue). The distributions
of the posterior median values are shown in histograms. The red curve illustrates the
ﬁtted shrinkage distribution for A′i. As a reference, the same curve for the full data
(group size 14, mean sequencing depth 5000), from which the parameter values in the
simulation was sampled, is shown in black.
The proposed model was evaluated using both simulated and real data.
First, we investigated the model’s ability to estimate the overdispersion pa-
rameter A′i, and the inﬂuence of the shrinkage approach. The evaluation was
based on simulated data, where the the average nucleotide compositions and
the overdispersion parameter were, for each position, set to values encountered
in real metagenomic data. The estimated overdispersion parameter values fol-
lowed the true values closely for a group size of 5 and a sequencing depth of
10,000 (Figure 5.9). When lowering the sequencing depth to 1000, the overdis-
persion parameter values showed larger deviance from the true values. However,
with help from the common prior distribution the correlation to the true values
was still evident. At the same parameter settings, the uncertainty in the esti-
mation of the overdispersion parameters was compared between the full model
and the model without shrinkage. The full model had much lower spread in
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its posterior distributions for A′i (when estimated without shrinkage, the mean
posterior standard deviation for A′i was 16 times higher). This was likewise re-
ﬂected in the uncertainty in the estimation of diﬀerences in nucleotide propor-
tions (δli), where using the shrinkage approach resulted in lower mean posterior
standard deviations for all studied cases, see Table 1 in Paper V. When varying
the group size while holding the sequencing depth ﬁxed at 10,000, it could be
seen that at a group size of 10 the model performed almost equally well with
and without shrinkage while at a group size of 3 the overdispersion parameters
totally lack information for estimation without a shrinkage approach (Figure
2 in Paper V). This shows that the proposed model, can accurately estimate
the overdispersion, even if there are few samples and low sequence coverage.
The use of a common prior for the overdispersion parameters reduced both the
deviance from true values and the uncertainty in the estimation.
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Figure 5.10: False positive rate (FPR) as a function of overdispersion, the latter rep-
resented by diﬀerent values for the scale parameter in the inverse gamma distribution
for the overdispersion parameter. Two diﬀerent means of ranking and three diﬀerent
group sizes are displayed: proposed model (circles), χ2-test (crosses), group size 3+3
(dotted line), 5+5 (dashed line) and 10+10 (solid line). The sequencing depth was
varied between samples, with a mean depth set to 1000. The proposed model was
able to maintain a low FPR for all levels of overdispersion. This was in contrast to
the χ2-test where the FPR increases rapidly when overdispersion was increased.
Next, the model’s ability to control the false positive rate (FPR) was exam-
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ined. When increasing the values of the overdispersion parameters, the FPR
was shown to be kept at a consistently low level for the proposed model (Figure
5.10). On the contrary, when instead applying a χ2-test, the FPR increased to
unsatisfactory levels. Thus, standard methods, such as the χ2-test, which does
not take the overdispersion in the data into account, can result in a very high
false positive rate.
The sensitivity of the model, measured as the ability to place the positions
with an eﬀect at the top of a ranking list, was evaluated using resampled data.
Samples from a publicly available dataset was randomly drawn to form groups
of a speciﬁc size, and eﬀects were added to 30 out of 237 studied positions.
Also, additional variability were added to some datasets, in order to evalu-
ate the performance at diﬀerent levels of overdispersion. First, the ranking
performance at a sequencing depth of 1000 and a group size of 5 was exam-
ined (Figure 4 in Paper V). As expected, the performance was increased with
larger eﬀect size. Nevertheless, even for an eﬀect size as low as 0.01, with low
overdispersion all the 20 top-ranked positions had a true eﬀect and the true
discovery rate (TDR) was estimated to 0.85 at position 30 in the ranking list.
With increased overdispersion, the ranking performance was reduced. At an
eﬀect size of 0.05, the estimated TDR at position 30 was 0.98, 0.84 and 0.71 for
low, intermediate and high level of overdispersion, respectively. The ordinary
χ2-test showed considerably lower performance for all settings, and especially
suﬀered at higher levels of overdispersion (Figure 4 in Paper V).
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Figure 5.11: True discovery rate as a function of position in the ranking list. The
results were estimated from resampled data, where the mean sequencing depth was
set to 1000, the average overdispersion level to intermediate and the mean eﬀect size
to 0.05. The group size was set to 3, 5 and 10 for the plot to the left, middle and
right, respectively (indicated as 3+3, 5+5 and 10+10). Three diﬀerent rankings are
displayed: Di based on the full model (solid line), Di based on the model without
shrinkage (dashed line) and χ2-test (dotted line).
The performance of the model was also evaluated for diﬀerent group sizes,
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showing an increased ranking ability for larger group sizes (Figure 5.11). At
a group size of 3 and a sequencing depth of 1000, there was a substantial dif-
ference in ranking performance between the full model and the model without
shrinkage. Lowering the sequencing depth to 100 (at a group size of 3) made
the performance even more dependent on the shrinkage approach, while for a
sequencing depth of 10,000 there was only a small diﬀerence in performance
between the models (Figure 6 in Paper V). Together, this shows that the pro-
posed model has a high sensitivity, even when the diﬀerences are small and the
number of samples low.
Finally, the model was tested in a case study, comparing the nucleotide
composition in communities of the bacteria Escherichia coli, before and after
travelling to India (Johnning et al., 2015). Data from the gene gyrA, which is
related to antibiotic resistance, was analysed. The model was able to pin-point
an increase of a mutation known to cause resistance against ﬂuoroquinolone
antibiotics (see Table 2 in Paper V). This shows that travelling can promote
the spread of antibiotic resistant bacteria.
In this study we show that it is possible to identify mutations also in the
complex datasets that microbial communities constitute. The proposed model
had a high ability to identify positions with a diﬀerence in nucleotide compo-
sition and to keep the false positive rate low, also under increased levels of
between-sample variability. The shrinkage approach made it possible to draw
accurate conclusions from sparse data, and reduced the uncertainty in the es-
timation. We conclude that tailored statistical models are important when
interpreting metagenomic sequencing data and can aid in increasing our un-
derstanding of complex microbial communities.
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Conclusions and outlook
In this thesis, bioinformatical and statistical methods for analysis of high-
dimensional data have been developed and applied in diﬀerent biological and
medical applications. Several types of molecular information have been utilised,
including data from high-throughput DNA sequencing and large-scale gene ex-
pression proﬁling using microarrays. A common challenge in all applications
has been to understand and properly model the variance structure in the data,
and thereby be able to separate the biological signal from the noise.
First, a method for identifying somatic mutations in exome sequencing
data from paired tumor–normal samples was established. By applying noise-
reduction methods adapted to the study design and statistical models dedicated
to detect somatic mutations, candidate nucleotide positions were identiﬁed in
a sensitive way. The false positive rate was reduced by careful inspection of
each candidate and custom-made ﬁlters based on the knowledge about the error
structure in the data. This resulted in, for example, identiﬁcation of both pre-
viously known and novel genes with recurrent somatic mutations in PCC/PGL,
with potential impact on malignancy. One of the novel genes, MYO5B, has
been further examined in functional studies. We could show that cell lines
transfected with MYO5B genes harbouring the found somatic mutations had a
signiﬁcantly increased proliferation and migration rate (data not yet published).
In addition, we recorded a higher mutation rate in malignant cases compared
to benign cases, something that has not been reported before in PCC/PGL
but has been encountered in other cancer forms. The results indicate that the
methods that were applied for identiﬁcation of somatic mutations have both
the necessary sensitivity and speciﬁcity.
It can be noted that results regarding the rate of somatic mutations in diﬀer-
ent cancer types and subgroups are something that need to be looked critically
upon, especially if comparing between studies. If not proper accounting for
false positives, these number can become distorted. Also, we note that the use-
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fulness of databases for comparing and evaluating the results may suﬀer from
inaccurate reports containing many false positives. If an artifact found in one
study is submitted to a database of known somatic mutations, variants found
at the same position in other studies are more likely to be judged as true, which
can make false ﬁndings at error-prone sites to accumulate. Controlling for false
positives is hence important also for preserving valuable scientiﬁc resources.
In paper II an III, we searched for somatic mutations in AML patients to
be used as biomarkers in personalised MRD analysis. Such candidates were
found in nearly all examined cases. In paper III, 17 of the found SNV:s were
tested in deep sequencing and of those 15 was deemed appropriate based on
having a low position-speciﬁc error rate. All 15 mutations that were utilised
in patient samples were shown to be useful for quantiﬁcation of remaining can-
cer cells. This suggests that the method to choose appropriate markers from
exome-sequencing data was well-adjusted. A statistical model for quantiﬁca-
tion of variant alleles in deep sequencing data was developed and tested in
MRD analysis. The level of detection was determined to 0.02%, meaning that
the proposed method meets the requirements for a useful MRD method (Schu-
urhuis et al., 2018). A comparison to standard MFC-MRD analysis showed
that the deep sequencing method had superior sensitivity. In Paper III, de-
tecting the variant alleles in blood instead of bone marrow was also tested
with good results. In blood, the levels of tumor cells may be substantially
lower than in bone marrow and hence even more sensitive methods are needed.
However, to be useful, a future method for regular monitoring of MRD levels
after remission in order to detect relapses early, need to be performed based
on blood samples due to the invasive procedure when taking a bone marrow
sample. We participate in an ongoing study where this is further evaluated,
showing promising results for detecting cancer cells with our proposed method
in blood samples several months before a relapse is evident. These ﬁndings
have therefore the potential to improve the diagnostics of AML, both in rela-
tion to making MRD analysis possible for all patients and to replace invasive
biopsies by blood samples.
In Paper IV, clustering based on miRNA gene expression proﬁles divided the
siNET tumors into subgroups. Thanks to a well characterised patient cohort,
the two groups with metastatic tumors could be shown to be associated to
clinically relevant parameters such as overall survival and proliferation rate.
Also, miR-375 was identiﬁed as a potential biomarker for survival based on
the miRNA gene expression arrays. This was validated in an independent
cohort of siNETs, using tissue microarrays, which showed association to survival
time in liver metastases. The supervised and unsupervised methods applied to
analyse this dataset were thus able to separate the biological signals from the
large levels of noise. Both the ﬁnding of clinical relevant molecular subgroups
and a potential biomarker for survival might aid in determining prognosis in
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individual patients, something that today is hard.
In Paper V, the focus shifted from ﬁnding mutations in individuals to in-
stead detecting diﬀerences on the nucleotide level between microbial communi-
ties encountering diﬀerent experimental conditions. Each condition is typically
sampled a number of times, to be able to take the often high biological vari-
ability into account, and hence groups of metagenomes are compared. We
developed a statistical model that takes both within- and between-sample vari-
ability into account and applies a shrinkage approach for more accurate variance
estimation. The proposed model was shown to have a good ability to detect
diﬀerences in nucleotide compositions, also in cases of high between-sample
variability, few samples and small diﬀerences. The performance was consid-
erable better than for a standard χ2-test. Thus, by using tailored statistical
methods mutations in microbial communities can be found, even when they
only exist in low proportions. This opens up for studying the mutational pro-
ﬁle of metagenomes, which is important in, for example, the urgent ﬁeld of
antibiotic resistance.
Analysis of high-throughput data from complex biological datasets is highly
dependent on detailed understanding of the experimental design, data genera-
tion and the underlying hypotheses. Appropriate methods need to be chosen
with care and - almost always - adopted to the speciﬁc application. In addi-
tion, potential biases and systematic errors, such as diﬀerences in experimental
setups between samples, needs to be taken into consideration. It should be em-
phasised that, as a statistician, you need to have an understanding of the ﬁeld
associated with the research question in order to select the most appropriate
methodology. It is therefore important with close and eﬃcient collaborations
to facilitate knowledge transfer between scientiﬁc disciplines. This has been
the case for the research reported in this thesis, which has been conducted
in interdisciplinary teams including competences in statistics, bioinformatics,
molecular biology and medicine. I am certain this has signiﬁcantly improved
the quality and impact of our results.
The experimental methods continue to evolve, with a higher throughput,
better quality and the ability to generate new types of information. Still, the
fundamental challenges in life science research addressed in this thesis will re-
main. Life rely on complex schemes of structures and processes, and is truly
high-dimensional in its nature. To deepen our understanding of these systems,
the use of statistical methods to account for the biological variability will con-
tinue to be crucial. Also, implementing the knowledge we gain, and advances
in experimental techniques, into our health care and other areas of society is
an important task and will remain dependent on interdisciplinary eﬀorts.
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